Bausch & Lomb Corp
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Bausch + Lomb (NYSE/TSX: BLCO) published research in Ophthalmology and Therapy showing enVista Aspire and enVista Aspire toric intraocular lenses provide good distance and intermediate vision in cataract patients. The study involved 84 patients and found high rates of visual acuity improvement with no serious adverse events. The lenses are designed to meet modern digital demands.
Healthcare stocks have outperformed the S&P 500, but some companies face challenges. Bausch + Lomb (BLCO) has declining EPS and free cash flow margins. Envista (NVST) shows weak sales growth and profitability. Progyny (PGNY) struggles with unit sales and capital returns. All three trade at forward P/E ratios of 16.9x, 17.5x, and 11.8x respectively.
Bausch + Lomb (NYSE/TSX: BLCO) announced two eye health therapies will advance to new trials. A dual-action eye drop for dry eye disease will move to Phase 3 after showing significant results at Day 15. An ocular surface pain treatment, BL1332, showed positive Phase 1b results and is in Phase 2 trials. Combined potential peak sales are estimated at over $2 billion.
Over the past 7 days, alphai's AI scored 2 news stories mentioning BLCO (Bausch & Lomb Corp). Coverage has been balanced: 1 bullish, 0 neutral, and 1 bearish.
Recent BLCO coverage spans technology, earnings and insider activity.
In the last 30 days, BLCO insiders filed 3 SEC Form 4 transactions — no purchases and 3 sales ($1.2M). The most active reporter was VON ESCHENBACH ANDREW C. with 2 filings.
Positive trial outcomes may support higher demand for BLCO's IOL products and could boost sales outlook.
Declining earnings and cash flow suggest weaker fundamentals, likely pressuring the stock lower.
Positive early‑stage data may lift sentiment and support a higher valuation outlook for BLCO as the programs progress toward potential FDA approval.
This is a routine insider open-market sale with no 10b5-1 plan stated, which can modestly affect near-term sentiment but is not a fundamental catalyst.
Guidance lift and board changes modestly improve the near-term execution narrative, but the article stresses the company remains structurally unprofitable.
alphai scores every news story that mentions BLCO with an AI model for sentiment and relevance, and aggregates insider trades from Bausch & Lomb Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
Bausch + Lomb (NYSE/TSX: BLCO) published research in Ophthalmology and Therapy showing enVista Aspire and enVista Aspire toric intraocular lenses provide good distance and intermediate vision in cataract patients. The study involved 84 patients and found high rates of visual acuity improvement with no serious adverse events. The lenses are designed to meet modern digital demands.
2 min readHealthcare stocks have outperformed the S&P 500, but some companies face challenges. Bausch + Lomb (BLCO) has declining EPS and free cash flow margins. Envista (NVST) shows weak sales growth and profitability. Progyny (PGNY) struggles with unit sales and capital returns. All three trade at forward P/E ratios of 16.9x, 17.5x, and 11.8x respectively.
3 min readBausch + Lomb (NYSE/TSX: BLCO) announced two eye health therapies will advance to new trials. A dual-action eye drop for dry eye disease will move to Phase 3 after showing significant results at Day 15. An ocular surface pain treatment, BL1332, showed positive Phase 1b results and is in Phase 2 trials. Combined potential peak sales are estimated at over $2 billion.
2 min readMunsch Frederick (SVP, Controller and CAO) sold 52,900 shares of Bausch & Lomb Corp (BLCO) at $16.78 ($0.89M total) on 2026-08-10.
2 min readBausch + Lomb (NYSE:BLCO) reported Q2 2026 revenue of $1.39B and narrowed its net loss to $14M. The company raised full-year 2026 revenue guidance to $5.44B to $5.54B. It also appointed four new directors after four resignations. The article assesses how the outlook and board changes may affect BLCO’s investment case.
6 min readVON ESCHENBACH ANDREW C. sold 18,559 shares of Bausch & Lomb Corp (BLCO) at an average of $16.53 ($16.50–$16.58, $0.31M total) across 2 trades over 2026-08-06 to 2026-08-07.
2 min readBausch Health Companies Inc. (NYSE:BHC) said CEO Thomas J. Appio was appointed to the board of Bausch + Lomb Corporation (NYSE:BLCO), effective Aug. 5, 2026. Other directors also joined, replacing several who resigned. Bausch Health said it holds about 87% of Bausch + Lomb’s common shares indirectly and supports its strategy.
2 min readBausch + Lomb (BLCO) said its experimental glaucoma eye drop BL1107 failed in a mid-stage trial of 159 patients. After 28 days it did not improve visual field scores, though it lowered eye pressure and showed no new safety issues. The company halted daily-drop development and will pursue a sustained-release implant for geographic atrophy instead.
3 min readBausch + Lomb (BLCO) reported Q2 2026 revenue of $1.394B, up 8% constant currency, and adjusted EBITDA of $246M, up 28%, with margin at 17.6%. Surgical, Pharmaceuticals, and Vision Care all grew. Full-year guidance raised to revenue $5.440B-$5.540B and adjusted EBITDA $1.025B-$1.075B. Net leverage fell to 4.7x.
7 min readBausch + Lomb (NYSE/TSX: BLCO) said its board will add four directors effective Aug. 5, 2026 at the request of Bausch Health, which owns about 87% of Bausch + Lomb shares. The company reported Q2 revenue of $1.394B and reaffirmed 2026 guidance: revenue $5.440B to $5.540B and Adjusted EBITDA $1.025B to $1.075B.
4 min read
